Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 438 across all filing types
Latest filing 2026-05-20 Interim / Quarterly Rep…
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Delårsrapport | Q1 2026” and contains detailed financial results, narrative CEO commentary, financial tables for January–March 2026, events during the quarter, and full management discussion sections. It is a comprehensive interim/quarterly report, not merely an earnings press release or notice of report publication. Therefore it should be classified as an Interim / Quarterly Report (Code: IR). Q1 2026
2026-05-20 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is explicitly titled “Interim Report | Q1 2026” for BioArctic and covers the first quarter of 2026. It provides detailed financial statements (revenues, profit, EPS, cash flows), key performance indicators, CEO commentary, project portfolio updates, and other substantive analysis. This is a comprehensive financial report for a period shorter than a full fiscal year rather than a brief earnings release or announcement. Therefore, it matches the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-20 English
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 – March 2027)
Regulatory Filings Classification · 82% confidence The document is a press release disclosing forward-looking revenue guidance for the Alzheimer’s treatment Leqembi and referencing an upcoming Q1 2026 report publication. It does not contain actual financial statements or formal results, nor is it announcing board changes, dividends, or an M&A transaction. It is a regulatory disclosure pursuant to the EU Market Abuse Regulation but not the report itself. This fits the catch-all “Regulatory Filings” category.
2026-05-15 English
Eisai prognosticerar 143,5 miljarder JPY i försäljning av Leqembi® för bolagets brutna räkenskapsår 2026 (april 2026 – mars 2027)
Regulatory Filings Classification · 80% confidence The document is a press release (in Swedish) announcing a partner’s sales forecast for Leqembi® for a future fiscal year and future publication date of the Q1 report. It does not contain actual financial statements or results, nor is it a management or investor presentation, nor an earnings release of actual period figures. It is a disclosure mandated under the EU Market Abuse Regulation. Thus it is best classified as a general regulatory announcement (Regulatory Filings, RNS).
2026-05-15 Swedish
Leqembi® Iqlik™ PDUFA-datum senarelagt till den 24 augusti i USA
Regulatory Filings
2026-05-08 English
Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
Regulatory Filings
2026-05-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.